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Letter to the Editor
Concerns in assessing risk fac-
tors for herpes zoster infection in 
multiple myeloma patients
TO THE EDITOR: R e c e n t  d e v e l o p m e n t s  o f  n e w  a g e n t s  s u c h 
as bortezomib and high-dose chemotherapy followed by 
stem cell transplantation for multiple myeloma have im-
proved the outcome of patients. However, it has also been 
reported that these therapies have impacted predisposing 
patients to various opportunistic infections [1]. A recent 
report of “The risk factors for herpes zoster in bortezomib 
treatment in patients with multiple myeloma” by Yi et al. 
has showed that the bortezomib itself might act as a risk 
factor for herpes zoster [2]. The authors additionally con-
cluded that the patients with low absolute lymphocyte counts 
(ALCs) at the time of bortezomib treatment initiation were 
at greater risk of herpes zoster during bortezomib treatment.
  I would like to comment several viewpoints on this inter-
esting article. Recent report of seroprevalence of Varicella- 
Zoster virus (VZV) in Korea showed that overall 87.6% 
had anti-VZV IgG antibody among the 887 patients [3]. 
And the seroprevalence rate exceeded 90% in subjects over 
11 years of age. With consideration of VZV vaccine avail-
ability in Korea, adults over 20 years who were not vacci-
nated and were seropositive by nautral infection of varicella, 
were more likely to have been the source of herpes zoster. 
Even though Yi et al. looked through the history of herpes 
zoster, prior history of varicella or antibody for VZV would 
be needed to see the potential risk factors for herpes zoster 
more precisely during the bortezomib therapy. 
  In addition, 91.7% of herpes zoster positive group and 
90.8% of herpes zoster negative group were also treated 
with dexamethasone in this study. Only 8.3-9.3% of patients 
were treated with bortozomib for itself. Not only bortezomib 
but also corticosteroid could have a role for the development 
of herpes zoster. And Chanan-Khan et al demonstrated ALCs 
and absolute neutrophil counts (ANCs) were comparable 
between patients regardless of herpes zoster state [4]. 
Notably the median ALCs and ANCs measured at the closest 
time point before the herpes zoster were significantly lower 
in bortezomib-treated patients compared with dexametha-
sone-treated patients. Therefore, the correlation of lower 
ALCs at the time of bortozomib treatment initiation and 
the risk of herpes zoster in this study should be interpreted 
carefully. There are reports that overall incidence (7-13%) 
of herpes virus infections during the treatment of bortezo-
mib appears to be similar to the incidence of those infections 
in myeloma, especially in the setting of advanced diseases 
and in patients treated with steroid [5]. Considering the 
high seroprevalence of VZV in Korea, 16.7% of incidence 
of herpes zoster in this study was not so surprisingly high. 
  I hope the studies of infectious complications including 
herpes zoster during the new era of multiple myeloma treat-
ment extend widely and these efforts could give the chance 
to find out the novel prophylactic strategy for the prevention 
of infection finally.
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